Mostrando 2 resultados de: 2
Filtros aplicados
Origen
scopus(2)
Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies (The Journal of Clinical Endocrinology and Metabolism (2021) 106:11 (e4666-e4679) DOI: 10.1210/clinem/dgab438)
OtherAbstract: Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200Palabras claves:Autores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopusTildacerfont in Adults with Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
ArticleAbstract: Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treatePalabras claves:17-hydroxyprogesterone, adrenocorticotropic hormone, androstenedione, Congenital adrenal hyperplasia, CRF-receptor antagonist, tildacerfontAutores:Barnes C.N., Huang M., Imel E.A., Madu I.J., Merke D.P., Moriarty D., Nakhle S., Newfield R.S., Richard J. Auchus, Sarafoglou K., Vogiatzi M.G.Fuentes:scopus